Longevica

May 29, 2023

Princeton, New Jersey | May 29, 2023 10:30 AM Eastern Daylight Time Longevica , a New Jersey-based science-driven company committed to uncovering the mechanisms of life extension, is actively seeking funding to support its groundbreaking research. With a team of dedicated scientists and philanthropists, Longevica relies on scientific data derived from fundamental experiments and comprehensive models to drive its mission. Established in 2009, Longevica's vision is to slow down aging, postpone age-related diseases, and ultimately eliminate them. Longevica’s research takes a contrarian approach aimed at identifying the mechanisms of life extension. The company embarked on an ambitious experiment involving the largest array of well-characterized pharmacological compounds in mice, making it the largest study conducted on long-lived mice to date. The study carried out at the renowned Jackson Laboratory in California, involved 20,000 long-lived female mice and examined the effects of 1,033 pharmacological compounds, for example Magnesium, Aspirin and so on. According to the company, the experiment proved to be a resounding success. Furthermore, through extensive big data analysis, Longevica identified two particular classes of compounds out of the total 62 that demonstrated a statistically significant correlation with life extension. This breakthrough provided crucial insights into the existence of mechanisms underlying life extension. Building upon these remarkable findings, the Longevica team dedicated the subsequent six years to the study of these two compound classes. Their research focused on understanding the mechanisms of action and the historical applications of these compounds in human medicine. As a result, the team in 2019-2021 established valid hypotheses regarding two mechanisms of life extension, with further details currently being specified. Both mechanisms aim to combat harmful compounds accumulation, leading to improved health and extended lifespan. These results were a surprise to all that were part of this experiment, truly showing the lack of knowledge and expectations we have regarding evolution and length of lifespan. The core paradigm of Longevica's life extension approach revolves around reducing “toxins”, thereby mitigating age-related diseases and promoting longevity. Following 14 years of research including their mice experiment and 15 million dollars in financing, Longevica is now poised to complete its aging research. “The truth is that we as humanity have a mission. After years of research, we still don’t understand the mechanisms that would enable us to move the survival curve to the right, meaning extending life span, even in mice. This research will be able to answer many if not all questions regarding life extension, bringing it out of a world of myth into reality. We plan on being able to turn our focus towards human life extension in our future research.” says Alexander Chikunov, founder of Longevica who provided all funds for this stage of research. Media contact: